European Investor
18 Sep 2026, 09:54
Charles River Laboratories Stock Rises 3%, Extends Gains Premarket After Argus Sets $330 Target
Charles River Laboratories shares closed Thursday at $281.67, up 3.02%, and were trading another 1.48% higher at $285.83 in Friday premarket trading.
The move came as Argus set a $330 price target on the stock. Based on Thursday’s close, the target implies roughly 17% upside.
Broader probable reasons behind the positive momentum include improving sentiment toward life-sciences tools and contract research companies, expectations for a recovery in biotech and pharmaceutical R&D spending, and the potential for stronger demand for outsourced drug-development services.
Charles River provides research models, laboratory services and preclinical development support to pharmaceutical and biotechnology companies, giving it exposure to changes in drug-development activity across the sector.
Friday’s premarket gain suggests the positive momentum has continued beyond Thursday’s analyst action, with investors focusing on the company’s longer-term earnings potential and a possible improvement in biopharma research spending.
Charles River Laboratories shares closed Thursday at $281.67, up 3.02%, and were trading another 1.48% higher at $285.83 in Friday premarket trading.
The move came as Argus set a $330 price target on the stock. Based on Thursday’s close, the target implies roughly 17% upside.
Broader probable reasons behind the positive momentum include improving sentiment toward life-sciences tools and contract research companies, expectations for a recovery in biotech and pharmaceutical R&D spending, and the potential for stronger demand for outsourced drug-development services.
Charles River provides research models, laboratory services and preclinical development support to pharmaceutical and biotechnology companies, giving it exposure to changes in drug-development activity across the sector.
Friday’s premarket gain suggests the positive momentum has continued beyond Thursday’s analyst action, with investors focusing on the company’s longer-term earnings potential and a possible improvement in biopharma research spending.
